Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2012-000765-20-FI
EUCTR2012-000765-20-FI
Active, not recruiting
Not Applicable

The Effect of Intravitreal Bevacizumab Injections in Patients with Macular Oedema Caused by AMD, CRVO or DME on the Plasticity of Nerves Studied by Visual Evoked Potentials

Kuopion yliopistollinen sairaala/silmätautien poliklinikka0 sitesNovember 20, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsAvastin

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Kuopion yliopistollinen sairaala/silmätautien poliklinikka
Status
Active, not recruiting
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 20, 2015
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Kuopion yliopistollinen sairaala/silmätautien poliklinikka

Eligibility Criteria

Inclusion Criteria

  • •All subjects are over 18 years old and subjects in AMD group are over 65 years old. The symptoms of decreased central vision or blurred vision is not allowed to have lasted longer than eigth weeks before entering the study. In CRVO group only non\-ischemic subtype is taken into this study.
  • •A control group consists healthy subjects over 18 years old without macular oedema.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 20
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 20

Exclusion Criteria

  • •\- Pregnancy
  • •\- The eye previously treated with anti\-VEGF injections
  • •\- Opthalmic surgery previously, only cataract surgery wihtout complications is allowed
  • •\- In AMD and CRVO groups diabetes is exclusion criteria.
  • •Anti\-VEGF injections or ophtalmic surgery of fellow eye is not an exclusion criteria.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Effect of diclofenac eye drop and Bevacizumab and Triamcinolone in preventing part of the retina edemaDiabetic retinopathy.Diabetic retinopathy
IRCT2017050833875N1Vice chancellor For Research Of Ahvaz Jundishapur University of Medical Sciences45
Completed
Phase 2
Intravitreal Bevacizumab in acute Branch Retinal Vein Occlusion(BRVO)Branch Retinal Vein occlusion.Other retinal vascular occlusions
IRCT201106214856N2Vice chancellor for research, Baqiyatallah University of Medical Science20
Recruiting
Phase 4
Efficacy of bevacizumab by intravitreal route in choroidal neovascular membrane of eye.
CTRI/2016/09/007288Govt medical college and sir takhtsinhji hospital bhavnagr30
Completed
Not Applicable
Evaluate the effect of intravitreal Bevacizumab injection for ocular proliferative diseaseschoroidal neovascularization,proliferative diabetic retinopathy, central retinal vein occlusion neovascular glaucoma
JPRN-UMIN000020467agasaki University Hospital90
Completed
Not Applicable
The effect of intra-vitreal injection of bevacizumab for vascular endothelial factor-related intraocular diseases.choroidal neovascularization, retinal vein occlusion, diabetic retinopathy, diabetic maculopathy, neovascular glaucoma
JPRN-UMIN000013974Department of Ophthalmology, Matsumoto Dental University3